Related coverage linked through entity extraction aliases.
Feb 26, 2026
Eli Lilly's oral GLP-1 drug orforglipron demonstrated 6-8% weight loss in type 2 diabetes patients compared to 4-5% with oral semaglutide in a phase 3 trial, though discontinuation rates were higher due to gastrointestinal side effects.
Feb 26, 2026
Oral semaglutide and the newly FDA-approved Wegovy pill are reshaping weight management by eliminating injections. Clinical trials show meaningful weight loss, while companies integrate the medications into subscription wellness programs.
Feb 25, 2026
New target trial emulation study finds GLP-1 receptor agonists associated with lower heart failure hospitalization risk versus DPP-4 inhibitors and similar risk to SGLT-2 inhibitors in type 2 diabetes patients.
Feb 25, 2026
Novo Nordisk announced it will reduce the list price of its semaglutide products Ozempic, Wegovy and Rybelsus to $675 starting January 1, 2027, representing cuts of up to 50 percent from current pricing.
Feb 25, 2026
The patent for semaglutide, the active ingredient in Ozempic, expires March 20, 2026. Indian pharmaceutical companies are preparing to launch generic versions, with prices expected to be 30-50% lower than branded products.
Feb 25, 2026
Novo Nordisk will reduce prices for Wegovy, Ozempic, and Rybelsus by up to 50% starting January 2027. Meanwhile, WADA investigates potential Olympic ban on weight loss drugs, and Brazil's Anvisa reports 65 suspected deaths linked to GLP-1 medications.
Feb 24, 2026
Metabolic and bariatric surgery provides greater cardiovascular protection than GLP-1 receptor agonists in individuals with obesity and type 2 diabetes, with a 52% relative risk reduction in major adverse cardiac events and all-cause mortality.
Feb 25, 2026
NATCO Pharma has licensed its semaglutide generic formulation to Eris Lifesciences for the Indian market, with a launch expected in March 2026 following CDSCO approval. The partnership targets type 2 diabetes management as the molecule loses patent exclusivity in India.
Feb 23, 2026
Microdosing GLP-1 medications like Ozempic and Wegovy has emerged as a weight-loss trend, but health experts warn there is no scientific data supporting the practice and caution about potential safety risks.
Feb 23, 2026
CagriSema demonstrated 23% weight loss in the REDEFINE 4 trial but failed to meet its primary endpoint of non-inferiority compared to tirzepatide's 25.5% weight loss. The company submitted an FDA application in December 2025 based on earlier pivotal trials.
Feb 20, 2026
Private prescriptions for GLP-1 weight-loss drugs in England are concentrated in affluent areas despite higher obesity rates in deprived regions. Online pharmacies face scrutiny for inadequate verification checks when dispensing these medications.
Feb 15, 2026
Recent reviews highlight expanding clinical benefits of GLP-1-based therapies, including antiinflammatory actions across multiple organs and cardiovascular risk reduction, with combination approaches emerging for obesity treatment.
Feb 17, 2026
Novo Nordisk sues telehealth companies over compounded weight-loss drugs as employers explore AI-based alternatives to costly GLP-1 medications. About 1 in 8 Americans now take GLP-1 drugs for weight loss or diabetes.
Feb 20, 2026
Tirzepatide, the active ingredient in Mounjaro, reduced alcohol intake by more than half in animal models and prevented relapse-like drinking behaviors, offering potential insights for alcohol use disorder treatment.
Feb 18, 2026
GLP-1 weight loss drugs show increasing efficacy but raise concerns about excessive weight loss, side effects, and the rise of unregulated compounded versions sold online.
Feb 16, 2026
Scientists in China report reversing Type 2 diabetes in a patient using stem cell therapy, while a separate study finds metformin may help women with diabetes live past 90. Both findings require larger trials.
Feb 14, 2026
UK and Brazil issue warnings about possible pancreatitis link to GLP-1 weight-loss drugs, while WADA monitors their use in Olympic athletes amid concerns about muscle loss and performance effects.
Feb 18, 2026
European regulators approved a 7.2mg "megadose" of Novo Nordisk's Wegovy involving three weekly injections. The Danish drugmaker filed suit against Hims & Hers after the telehealth company briefly launched a compounded oral semaglutide product.
Feb 17, 2026
Novo Nordisk's investigational dual agonist CagriSema demonstrated superior efficacy to Ozempic in a phase 3 trial for type 2 diabetes patients, while the company faces market share losses to Eli Lilly in the GLP-1 space.
Feb 17, 2026
Novo Nordisk announced on February 4, 2026, that oral semaglutide previously marketed as Rybelsus will be rebranded as oral Ozempic, with availability expected in Q2 2026. The company also filed a patent infringement lawsuit against Hims & Hers over compounded oral semaglutide products.
